1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Spending Outlook
4.2. Forecast Factors – Relevance & Impact
4.2.1. Adoption of Drugs
4.2.2. Disease Prevalence
4.2.3. Reimbursement scenario
4.2.4. Regulatory Scenario
4.2.5. Product in Pipeline
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
5. Market Context
5.1. Drug Type vs Indication Analysis
5.2. Strategic Promotional Analysis, By Key Manufacturers
5.3. Key Regulations
5.4. Porter’s Five Forces Analysis
5.5. PESTLE Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 financial analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue By Product
6.4.2. Revenue By Dosage Form
6.4.3. Revenue By Country
6.5. 2020 Market Scenario
6.6. Quarter by Quarter Forecast
6.7. Projected recovery Quarter
6.8. Recovery Scenario – Short term, Midterm and Long Term Impact Global
7. Global Eye Infection treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030
7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015 – 2019
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020 – 2030
8.3.1. Antibiotics
8.3.1.1. Sulfonamides
8.3.1.2. Macrolides
8.3.1.3. Erythromycin
8.3.1.4. Chloramphenicol
8.3.1.5. Aminoglycosides
8.3.1.6. Fluoroquinolones
8.3.1.7. Vancomycin
8.3.1.8. Tetracyclines
8.3.2. Antivirals
8.3.2.1. Thymidine-Based Nucleoside Analogues (Trifluridine)
8.3.2.2. Thymidine Phosphorylase Inhibitors (Trifluridine)
8.3.2.3. Acyclic Nucleoside Analogue of 2′Deoxyguanasine (Ganciclovir)
8.3.2.4. Acyclic Guanine Nucleoside Analog (Acyclovir)
8.3.2.5. Others
8.3.3. Antifungals
8.3.3.1. Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
8.3.3.2. Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
8.3.3.3. Pyrimidines
8.3.3.4. Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
8.3.3.5. Others
8.3.4. Antihistamines
8.3.5. Corticosteroids
8.3.6. Glucocorticoids
8.4. Market Attractiveness Analysis By Drug Class
9. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Dosage Form
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Dosage Form, 2015 – 2019
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Dosage Form, 2020 – 2030
9.3.1. Tablet
9.3.2. Capsule
9.3.3. Ophthalmic Ointment
9.3.4. Eye Drops
9.3.5. Others
9.4. Market Attractiveness Analysis By Dosage Form
10. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Indication
10.1.Introduction / Key Findings
10.2.Historical Market Size (US$ Mn) Analysis By Indication, 2015 – 2019
10.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 – 2030
10.3.1. Conjunctivitis
10.3.2. Keratitis
10.3.3. Endophthalmitis
10.3.4. Blepharitis
10.3.5. Stye or Sty (Hordeolum)
10.3.6. Uveitis
10.3.7. Cellulitis
10.3.8. Ocular herpes
10.4.Market Attractiveness Analysis By Indication
11. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Causative Agent
11.1.Introduction / Key Findings
11.2.Historical Market Size (US$ Mn) Analysis By Causative Agent, 2015 – 2019
11.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Causative Agent, 2020 – 2030
11.3.1. Virus
11.3.2. Bacteria
11.3.3. Fungus
11.3.4. Allergens
11.4.Market Attractiveness Analysis By Causative Agent
12. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel
12.1.Introduction / Key Findings
12.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 – 2019
12.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 – 2030
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Drug Stores
12.3.4. Online Pharmacy
12.4.Market Attractiveness Analysis By Distribution Channel
13. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region
13.1.Introduction
13.2.Historical Market Size (US$ Mn) Analysis By Region, 2015 – 2019
13.3.Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 – 2030
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4.Market Attractiveness Analysis By Region
14. North America Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2020 – 2030
14.4.1. By Country
14.4.1.1. U.S.
14.4.1.2. Canada
14.4.2. By Drug Class
14.4.3. By Dosage Form
14.4.4. By Indications
14.4.5. By Causative Agent
14.4.6. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Drug Class
14.5.3. By Dosage Form
14.5.4. By Indications
14.5.5. By Causative Agent
14.5.6. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants – Intensity Mapping
14.8. Drivers and Restraints – Impact Analysis
15. Latin America Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2020 – 2030
15.4.1. By Country
15.4.1.1. Brazil
15.4.1.2. Mexico
15.4.1.3. Rest of Latin America
15.4.2. By Drug Class
15.4.3. By Dosage Form
15.4.4. By Indications
15.4.5. By Causative Agent
15.4.6. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Drug Class
15.5.3. By Dosage Form
15.5.4. By Indications
15.5.5. By Causative Agent
15.5.6. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants – Intensity Mapping
15.8. Drivers and Restraints – Impact Analysis
16. Europe Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
16.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
16.4.1. By Country
16.4.1.1. Germany
16.4.1.2. U.K.
16.4.1.3. France
16.4.1.4. France
16.4.1.5. Italy
16.4.1.6. Spain
16.4.1.7. Russia
16.4.1.8. Rest of Europe
16.4.2. By Drug Class
16.4.3. By Dosage Form
16.4.4. By Indications
16.4.5. By Causative Agent
16.4.6. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Drug Class
16.5.3. By Dosage Form
16.5.4. By Indications
16.5.5. By Causative Agent
16.5.6. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants – Intensity Mapping
16.8. Drivers and Restraints – Impact Analysis
17. South Asia Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 – 2019
17.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
17.4.1. By Country
17.4.1.1. India
17.4.1.2. Thailand
17.4.1.3. Indonesia
17.4.1.4. Malaysia
17.4.1.5. Rest of South Asia
17.4.2. By Drug Class
17.4.3. By Dosage Form
17.4.4. By Indications
17.4.5. By Causative Agent
17.4.6. By Distribution Channel
17.5.Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Drug Class
17.5.3. By Dosage Form
17.5.4. By Indications
17.5.5. By Causative Agent
17.5.6. By Distribution Channel
17.6.Market Trends
17.7.Key Market Participants – Intensity Mapping
17.8.Drivers and Restraints – Impact Analysis
18. East Asia Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 – 2019
18.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
18.4.1. By Country
18.4.1.1. China
18.4.1.2. Japan
18.4.1.3. South Korea
18.4.2. By Drug Class
18.4.3. By Dosage Form
18.4.4. By Indications
18.4.5. By Causative Agent
18.4.6. By Distribution Channel
18.5.Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Drug Class
18.5.3. By Dosage Form
18.5.4. By Indications
18.5.5. By Causative Agent
18.5.6. By Distribution Channel
18.6 .Market Trends
18.7. Key Market Participants – Intensity Mapping
18.8. Drivers and Restraints – Impact Analysis
19. Oceania Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
19.1.Introduction
19.2.Pricing Analysis
19.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
19.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
19.4.1. By Country
19.4.1.1. Australia
19.4.1.2. New Zealand
19.4.2. By Drug Class
19.4.3. By Dosage Form
19.4.4. By Indications
19.4.5. By Causative Agent
19.4.6. By Distribution Channel
19.5.Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Drug Class
19.5.3. By Dosage Form
19.5.4. By Indications
19.5.5. By Causative Agent
19.5.6. By Distribution Channel
19.6.Market Trends
19.7.Key Market Participants – Intensity Mapping
19.8.Drivers and Restraints – Impact Analysis
20. Middle East and Africa Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
20.1.Introduction
20.2.Pricing Analysis
20.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
20.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
20.4.1. By Country
20.4.1.1. GCC Countries
20.4.1.2. Turkey
20.4.1.3. Northern Africa
20.4.1.4. South Africa
20.4.1.5. Rest of Middle East and Africa
20.4.2. By Drug Class
20.4.3. By Dosage Form
20.4.4. By Indications
20.4.5. By Causative Agent
20.4.6. By Distribution Channel
20.5.Market Attractiveness Analysis
20.5.1. By Country
20.5.2. By Drug Class
20.5.3. By Dosage Form
20.5.4. By Indications
20.5.5. By Causative Agent
20.5.6. By Distribution Channel
20.6.Market Trends
20.7.Key Market Participants – Intensity Mapping
20.8.Drivers and Restraints – Impact Analysis
21. Emerging Countries Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030
21.1.Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2.China Eye Infection treatment Market Analysis
21.2.1. Introduction
21.2.2. Pricing Analysis
21.2.3. PEST Analysis
21.2.4. Market Value Proportion Analysis by Market Taxonomy
21.2.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
21.2.5.1. By Drug Class
21.2.5.2. By Dosage Form
21.2.5.3. By Indications
21.2.5.4. By Causative Agent
21.2.5.5. By Distribution Channel
21.2.6. China Eye Infection treatment Market – Competition Landscape
21.2.7. China – Trade Analysis
21.3.India Eye Infection treatment Market Analysis
21.3.1. Introduction
21.3.2. Pricing Analysis
21.3.3. PEST Analysis
21.3.4. Market Value Proportion Analysis by Market Taxonomy
21.3.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
21.3.5.1. By Drug Class
21.3.5.2. By Dosage Form
21.3.5.3. By Indications
21.3.5.4. By Causative Agent
21.3.5.5. By Distribution Channel
21.3.6. India Eye Infection treatment Market – Competition Landscape
21.4.Brazil Eye Infection treatment Market Analysis
21.4.1. Introduction
21.4.2. Pricing Analysis
21.4.3. PEST Analysis
21.4.4. Market Value Proportion Analysis by Market Taxonomy
21.4.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
21.4.5.1. By Drug Class
21.4.5.2. By Dosage Form
21.4.5.3. By Indications
21.4.5.4. By Causative Agent
21.4.5.5. By Distribution Channel
21.4.6. Brazil Eye Infection treatment Market – Competition Landscape
22. Market Structure Analysis
22.1.Market Analysis by Tier of Companies (Eye Infection treatment)
22.2.Market Concentration
22.3.Market Share Analysis of Top Players
22.4.Market Presence Analysis
22.4.1. By Regional footprint of Players
22.4.2. Product foot print by Players
22.4.3. Channel Foot Print by Players
23. Competition Analysis
23.1.Competition Dashboard
23.2.Pricing Analysis by Competition
23.3.Competition Benchmarking
23.4.Competition Deep Dive
23.4.1. Allergan plc
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Profitability by Market Segments (Product/Channel/Region)
23.4.1.4. Sales Footprint
23.4.1.5. Strategy Overview
23.4.1.5.1. Marketing Strategy
23.4.1.5.2. Product Strategy
23.4.1.5.3. Channel Strategy
23.4.2. Alcon Laboratories, Inc.
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Profitability by Market Segments (Product/Channel/Region)
23.4.2.4. Sales Footprint
23.4.2.5. Strategy Overview
23.4.2.5.1. Marketing Strategy
23.4.2.5.2. Product Strategy
23.4.2.5.3. Channel Strategy
23.4.3. Bausch Health Companies Inc.
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Profitability by Market Segments (Product/Channel/Region)
23.4.3.4. Sales Footprint
23.4.3.5. Strategy Overview
23.4.3.5.1. Marketing Strategy
23.4.3.5.2. Product Strategy
23.4.3.5.3. Channel Strategy
23.4.4. Pfizer Inc.
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Profitability by Market Segments (Product/Channel/Region)
23.4.4.4. Sales Footprint
23.4.4.5. Strategy Overview
23.4.4.5.1. Marketing Strategy
23.4.4.5.2. Product Strategy
23.4.4.5.3. Channel Strategy
23.4.5. Akron Pharma Inc.
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Profitability by Market Segments (Product/Channel/Region)
23.4.5.4. Sales Footprint
23.4.5.5. Strategy Overview
23.4.5.5.1. Marketing Strategy
23.4.5.5.2. Product Strategy
23.4.5.5.3. Channel Strategy
23.4.6. Sanofi S.A.
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Profitability by Market Segments (Product/Channel/Region)
23.4.6.4. Sales Footprint
23.4.6.5. Strategy Overview
23.4.6.5.1. Marketing Strategy
23.4.6.5.2. Product Strategy
23.4.6.5.3. Channel Strategy
23.4.7. GlaxoSmithKline plc
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Profitability by Market Segments (Product/Channel/Region)
23.4.7.4. Sales Footprint
23.4.7.5. Strategy Overview
23.4.7.5.1. Marketing Strategy
23.4.7.5.2. Product Strategy
23.4.7.5.3. Channel Strategy
23.4.8. Intas Pharmaceuticals Ltd
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Profitability by Market Segments (Product/Channel/Region)
23.4.8.4. Sales Footprint
23.4.8.5. Strategy Overview
23.4.8.5.1. Marketing Strategy
23.4.8.5.2. Product Strategy
23.4.8.5.3. Channel Strategy
23.4.9. Johnson & Johnson Services, Inc.
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Profitability by Market Segments (Product/Channel/Region)
23.4.9.4. Sales Footprint
23.4.9.5. Strategy Overview
23.4.9.5.1. Marketing Strategy
23.4.9.5.2. Product Strategy
23.4.9.5.3. Channel Strategy
23.4.10. Macleods Pharmaceuticals Ltd.
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Profitability by Market Segments (Product/Channel/Region)
23.4.10.4. Sales Footprint
23.4.10.5. Strategy Overview
23.4.10.5.1. Marketing Strategy
23.4.10.5.2. Product Strategy
23.4.10.5.3. Channel Strategy
23.4.11. Merck & Co., Inc.
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Profitability by Market Segments (Product/Channel/Region)
23.4.11.4. Sales Footprint
23.4.11.5. Strategy Overview
23.4.11.5.1. Marketing Strategy
23.4.11.5.2. Product Strategy
23.4.11.5.3. Channel Strategy
23.4.12. Mylan N.V.
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Profitability by Market Segments (Product/Channel/Region)
23.4.12.4. Sales Footprint
23.4.12.5. Strategy Overview
23.4.12.5.1. Marketing Strategy
23.4.12.5.2. Product Strategy
23.4.12.5.3. Channel Strategy
23.4.13. Teva Pharmaceutical Industries Ltd.
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Profitability by Market Segments (Product/Channel/Region)
23.4.13.4. Sales Footprint
23.4.13.5. Strategy Overview
23.4.13.5.1. Marketing Strategy
23.4.13.5.2. Product Strategy
23.4.13.5.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
【免責事項】
https://www.marketreport.jp/reports-disclaimer